<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">397496680</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180308164522.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">161202e199503  xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1016/S1010-7940(05)80061-2</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)oxford-10.1016/S1010-7940(05)80061-2</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
   <subfield code="a">Suppressed fibrinolysis after administration of low-dose aprotinin: reduced level of plasmin-alpha2-plasmin inhibitor complexes and postoperative blood loss</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Various clinical investigation have shown that aprotinin therapy reducesbleeding after open-heart operations. In this study low-dose aprotinin,30,000 KIU/kg in the cardiopulmonary bypass (CPB) priming volume and 7,500KIU/kg intravenously each hour during CPB, was used in ten patientsundergoing primary myocardial revascularization or surgery for valvulardiseases. Another ten patients served as controls. Blood loss, plateletcount and plasma levels of hemoglobin, antithrombin III, fibrinogen,fibrinogen degradation products (FDP), total plasmin inhibitor andalpha2-plasmin inhibitor-plasmin complexes were evaluated at ninepreoperative, intraoperative and postoperative points. Intraoperative andpostoperative blood loss was significantly reduced in the aprotinin group.There was no significant difference between the two groups in plateletcount and levels of hemoglobin and antithrombin III. A significant increasein FDP during CPB in the control group indicated hyperfibrinolysis. Thelevels of plasmin inhibitor were significantly reduced during CPB in thecontrol group. The alpha 2- plasmin inhibitor-plasma complex levels,indicating the plasmin activity, were significantly reduced in theaprotinin group. These results confirmed that low-dose aprotinin reducedblood loss with the prevention of hyperfibrinolysis during CPB anddemonstrated improved hemostasis.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">© Springer-Verlag 1995</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">European Journal of Cardio-Thoracic Surgery</subfield>
   <subfield code="d">Elsevier Science B.V.</subfield>
   <subfield code="g">9/3(1995-03), 143-145</subfield>
   <subfield code="x">1010-7940</subfield>
   <subfield code="q">9:3&lt;143</subfield>
   <subfield code="1">1995</subfield>
   <subfield code="2">9</subfield>
   <subfield code="o">ejcts</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1016/S1010-7940(05)80061-2</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1016/S1010-7940(05)80061-2</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">European Journal of Cardio-Thoracic Surgery</subfield>
   <subfield code="d">Elsevier Science B.V</subfield>
   <subfield code="g">9/3(1995-03), 143-145</subfield>
   <subfield code="x">1010-7940</subfield>
   <subfield code="q">9:3&lt;143</subfield>
   <subfield code="1">1995</subfield>
   <subfield code="2">9</subfield>
   <subfield code="o">ejcts</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">CC BY-NC-4.0</subfield>
   <subfield code="u">http://creativecommons.org/licenses/by-nc/4.0</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-oxford</subfield>
  </datafield>
 </record>
</collection>
